Locally Advanced or Metastatic Pancreatic Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

April 3, 2018

Primary Completion Date

April 20, 2020

Study Completion Date

April 20, 2020

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

chemotherapy: TS-1, Leucovorin and Gemcitabine

Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.

Trial Locations (2)

Unknown

China Medical University Hospital, Taichung

Chang-Gung Memorial Hospital, Taipei

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

collaborator

Kaohsiung Medical University

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER

NCT03559348 - Locally Advanced or Metastatic Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter